Big Pharma wins more drug approvals, but fewer new sales

The good news: Big Pharma is doing better at winning regulatory approvals and advancing drugs to late-stage development. The bad: Newly approved meds aren't expected to deliver peak sales as high as those approved in prior years, a report from Deloitte and Thomson Reuters found. Report